Develops RNA-based medicines that restore normal levels of proteins missing in genetic diseases like Dravet syndrome.
Develops RNA-based medicines that restore normal levels of proteins missing in genetic diseases like Dravet syndrome.
Has no medicine on the market, so it lives on cash from shareholders and partner payments, and nearly all its value rests on one lead medicine for Dravet syndrome. The approach raises output from the healthy copy of the affected gene, and Biogen is a partner on its central-nervous-system work.
Moat: narrow (IP / patents, process know-how). Proprietary TANGO antisense oligonucleotide technology targets gene splicing to restore protein levels.
Headquarters: Bedford, Massachusetts, US · Founded: 2014 · Employees: 170
Size Stoke Therapeutics (STOK) is a United States Health Care company (Biotechnology) with a market value of $1.75B, the 1864th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.69 on 18 Nov 2026.
Performance Over six months the shares fell 11.9%, against +7.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 86.3% over the last twelve months (peer median +19.3%); the operating margin is -913.1% (peer median -0.2%).
Valuation It trades at 50.6× enterprise value to sales against a peer median of 10.9× (4th most expensive of 17).
Short interest Short interest is 16.4% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $28.2M | $184M | $36.6M | $8.78M | $12.4M |
| Revenue growth | — | +405% | +316% | -29% | — |
| Gross profit | $23.9M | $180M | $32.1M | $4.05M | $8.87M |
| EBITDA | -$253M | -$16.4M | -$96.9M | -$110M | -$101M |
| Net income | -$243M | -$6.88M | -$89.0M | -$105M | -$101M |
| Free cash flow | -$216M | $44.9M | -$87.1M | -$82.7M | -$35.8M |
| Capital expenditure | $5.41M | $670,000 | $203,000 | $1.62M | $3.96M |
| Total debt | $1.92M | $4.15M | $4.77M | $6.83M | $5.08M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Stoke Therapeutics STOK | $1.75B | -12% | -86% | -913% | 50.6× | n/a |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 4.4× | 10.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STOK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.3% | -6.2% | 7th highest of 20 |
| 6-month return | -11.9% | +7.3% | 8th lowest of 20 |
| Distance from 52-week high | -33.6% | -33.1% | 11th highest of 21 |
| Revenue growth (TTM) | -86.3% | +19.3% | lowest of 17 |
| Operating margin | -913.1% | -0.2% | 4th lowest of 18 |
| EV / Sales | 50.6× | 10.9× | 4th most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |